Kite Pharma Announces $11.9 Billion Acquisition by Gilead Sciences

August 28, 2017

S&C represents Kite Pharma, Inc. in its definitive agreement to be acquired by Gilead Sciences, Inc. for $180.00 per share in cash in a transaction which values Kite at approximately $11.9 billion.

The S&C team on the transaction was led by Alison Ressler and Eric Krautheimer, along with Matthew Barnett, Ravi Mahesh, Edward Xia, Anel Loubser, Vartika Jain, Emily Yi and Kelly Meric. Matthew Friestedt, Regina Readling, Jeannette Braun, Kelsey Baldwin and Joshua Green advised on executive compensation and benefits matters; Nader Mousavi and Mark Schenkel advised on intellectual property matters; Ronald Creamer advised on tax matters; and Joseph Matelis, Juan Rodriguez, Eric Queen and Patrick Gorman advised on antitrust and competition matters.